163 related articles for article (PubMed ID: 30396879)
1. Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method.
Danışman Kalındemirtaş F; Birman H; Candöken E; Bilgiş Gazioğlu S; Melikoğlu G; Kuruca S
Balkan Med J; 2019 Feb; 36(2):96-105. PubMed ID: 30396879
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of apigenin, a plant flavonoid, for imatinib-sensitive and resistant chronic myeloid leukemia cells.
Solmaz S; Adan Gokbulut A; Cincin B; Ozdogu H; Boga C; Cakmakoglu B; Kozanoglu I; Baran Y
Nutr Cancer; 2014; 66(4):599-612. PubMed ID: 24669768
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of human chronic myelogenous leukemia K562 cell growth following combination treatment with resveratrol and imatinib mesylate.
Wang XJ; Li YH
Genet Mol Res; 2015 Jun; 14(2):6413-8. PubMed ID: 26125846
[TBL] [Abstract][Full Text] [Related]
4. Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Tolomeo M; Grimaudo S; Di Cristina A; Pipitone RM; Dusonchet L; Meli M; Crosta L; Gebbia N; Invidiata FP; Titone L; Simoni D
Cancer Lett; 2008 Jul; 265(2):289-97. PubMed ID: 18374481
[TBL] [Abstract][Full Text] [Related]
5. Interactions of N-desmethyl imatinib, an active metabolite of imatinib, with P-glycoprotein in human leukemia cells.
Mlejnek P; Dolezel P; Faber E; Kosztyu P
Ann Hematol; 2011 Jul; 90(7):837-42. PubMed ID: 21225261
[TBL] [Abstract][Full Text] [Related]
6. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
7. [Effect of phenylhexyl isothiocyanate on drug-resistance to imatinib in K562/G01 cell line].
Wu RJ; Huang YQ; Ma XD
Zhonghua Xue Ye Xue Za Zhi; 2013 Feb; 34(2):149-52. PubMed ID: 23611223
[TBL] [Abstract][Full Text] [Related]
8. [Establishment of an imatinib resistant cell line K562/G01 and its characterization].
Qi J; Peng H; Gu ZL; Liang ZQ; Yang CZ
Zhonghua Xue Ye Xue Za Zhi; 2004 Jun; 25(6):337-41. PubMed ID: 15308010
[TBL] [Abstract][Full Text] [Related]
9. Knock-down of CIAPIN1 sensitizes K562 chronic myeloid leukemia cells to Imatinib by regulation of cell cycle and apoptosis-associated members via NF-κB and ERK5 signaling pathway.
Wang J; Li Q; Wang C; Xiong Q; Lin Y; Sun Q; Jin H; Yang F; Ren X; Pang T
Biochem Pharmacol; 2016 Jan; 99():132-45. PubMed ID: 26679828
[TBL] [Abstract][Full Text] [Related]
10. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
11. [Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
Ge YQ; Cheng RB; Yang B; Huang Z; Chen Z
Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2389-95. PubMed ID: 26591531
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of 3-hydroxyflavone and imatinib mesylate increases apoptotic cell death of imatinib mesylate-resistant leukemia cells.
Kim JH; Song M; Kang GH; Lee ER; Choi HY; Lee C; Kim JH; Kim Y; Koo BN; Cho SG
Leuk Res; 2012 Sep; 36(9):1157-64. PubMed ID: 22770910
[TBL] [Abstract][Full Text] [Related]
13. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway.
Li X; Miao H; Zhang Y; Li W; Li Z; Zhou Y; Zhao L; Guo Q
Arch Toxicol; 2015 Jan; 89(1):121-36. PubMed ID: 24671465
[TBL] [Abstract][Full Text] [Related]
15. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
16. [Effect of ZD6474 on the proliferation of imatinib-resistant K562 cells].
Jia HY; Wu XM; Wang ZY; Deng XY; Lin Z; Feng GL; Huang WL
Zhonghua Xue Ye Xue Za Zhi; 2010 Jun; 31(6):371-5. PubMed ID: 21122350
[TBL] [Abstract][Full Text] [Related]
17. Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells.
James AR; Unnikrishnan BS; Priya R; Joseph MM; Manojkumar TK; Raveendran Pillai K; Shiji R; Preethi GU; Kusumakumary P; Sreelekha TT
Tumour Biol; 2017 Mar; 39(3):1010428317695946. PubMed ID: 28345463
[TBL] [Abstract][Full Text] [Related]
18. Flavones inhibit the proliferation of human tumor cancer cell lines by inducing apoptosis.
Kilani-Jaziri S; Frachet V; Bhouri W; Ghedira K; Chekir-Ghedira L; Ronot X
Drug Chem Toxicol; 2012 Jan; 35(1):1-10. PubMed ID: 21777131
[TBL] [Abstract][Full Text] [Related]
19. [Anti-Leukemia Effect and Mechanism of Oridonin on Imatinib-Sensitive and Imatinib-Resistant K562 Cells].
Shan QQ; Guo Y; Gong YP; Lin J; Wang YS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Oct; 25(5):1378-1383. PubMed ID: 29070111
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
